Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.3836
Abstract: Importance Isocitrate dehydrogenase 1 (IDH1) variations occur in up to approximately 20% of patients with intrahepatic cholangiocarcinoma. In the ClarIDHy trial, progression-free survival as determined by central review was significantly improved with ivosidenib vs placebo.… read more here.
Keywords: trial; cholangiocarcinoma idh1; idh1 mutation; placebo ... See more keywords
Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Clinical Pharmacology"
DOI: 10.1007/s00228-019-02673-6
Abstract: PurposeTo assess the effect of ethnicity, food, and itraconazole (strong CYP3A4 inhibitor) on the pharmacokinetics of ivosidenib after single oral doses in healthy subjects.MethodsThree phase 1 open-label studies were performed. Study 1: Japanese and Caucasian… read more here.
Keywords: pharmacokinetics ivosidenib; effect; healthy subjects; subjects received ... See more keywords
An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2022.2138331
Abstract: ABSTRACT Introduction The combination of gemcitabine and cisplatin remains the standard-of-care first-line therapeutic option in patients with the unresectable disease based on the encouraging phase II and phase III trials (ABC-02). Recently, the combination of… read more here.
Keywords: idh1 mutant; cholangiocarcinoma; combination; ivosidenib ... See more keywords
Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?
Sign Up to like & getrecommendations! Published in 2021 at "Expert Review of Precision Medicine and Drug Development"
DOI: 10.1080/23808993.2021.1915126
Abstract: ABSTRACT Introduction: Cholangiocarcinomas (CCAs) are rare and heterogeneous malignancies associated with poor prognosis, with most of the patients presenting with advanced disease at diagnosis. The recent advent of molecular profiling has led to the identification… read more here.
Keywords: idh mutant; mutant cholangiocarcinoma; idh; ivosidenib idh ... See more keywords
The IDH1 Inhibitor Ivosidenib May Slow IDH1-Mutant Glioma Progression.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2020-095
Abstract: Ivosidenib, an inhibitor of mutant IDH1, was safe and showed early evidence of efficacy in glioma. read more here.
Keywords: ivosidenib; glioma; inhibitor ivosidenib; idh1 inhibitor ... See more keywords